- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 13:26 | EU approves SpringWorks' Ezmekly for neurofibromatosis type 1 treatment | ||
| Fr | Daiichi Sankyo and AstraZeneca's Enhertu gains breakthrough therapy status | ||
| Do | FDA grants fast track designation to Sanofi's SAR446597 | ||
| Mi | FDA grants orphan status for AlzeCure's pain drug candidate | ||
| Di | Sun Pharmaceutical launches Leqselvi in US for severe alopecia areata | ||
| 14.07. | Golden Age Health secures rights to promote LX-101 gene therapy in China | ||
| 11.07. | Secarna, Vect-Horus partner to develop RNA-targeted therapeutics | ||
| 10.07. | Simcere Pharmaceutical seeks China approval for atopic dermatitis treatment | ||
| 09.07. | Rallybio sells REV102 programme to Recursion for up to $25m | ||
| 08.07. | Sagent, Qilu partner to commercialise complex injectable products in US | ||
| 07.07. | Biosynth opens expanded GMP bioconjugation facility in Germany | ||
| 04.07. | FDA approves Hikma's Tyzavan for multiple infections | ||
| 03.07. | FDA grants priority review for MSD's Winrevair | ||
| 02.07. | Formycon, Bio Usawa to introduce ophthalmic medicine in Sub-Saharan Africa | ||
| 01.07. | Simtra BioPharma constructs production manufacturing building in Germany | ||
| 30.06. | Mabwell signs Albipagrastim alfa deal with Qilu Pharmaceutical | ||
| 27.06. | Innovent's Mazdutide receives approval for chronic weight management in China | ||
| 26.06. | FDA approves Plus Therapeutics' Reyobiq for paediatric brain cancer | ||
| 25.06. | EC grants orphan drug status to JR-446 for MPS IIIB | ||
| 24.06. | Optime Care collaborates with Tilde Sciences for Vecamyl tablets | ||
| 23.06. | Archeus Technologies gets FDA approval for ART-101 application | ||
| 20.06. | CHMP endorses ExCellThera's stem cell transplantation product | ||
| 19.06. | Johnson & Johnson submits sBLA to FDA to extend use of ustekinumab | ||
| 18.06. | Ferrer's progressive supranuclear palsy therapy gains FDA fast track status | ||
| 17.06. | FDA grants fast-track status to SolasCure's gel for calciphylaxis ulcers |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .